The company’s insurance unit shows improvement as it posts a medical benefit ratio of 84.6%, down from 87.3% last year
Category: Health
On May 6, 2026, CVS Health reported a strong performance for the first quarter, exceeding earnings and revenue estimates, and raised its full-year guidance for 2026. The healthcare giant, which operates the largest pharmacy chain in the United States, announced adjusted earnings per share (EPS) of $2.57, significantly surpassing the expected $2.20, and total revenues of $100.43 billion, beating analyst forecasts of $95.09 billion.
This impressive quarterly performance has prompted CVS to revise its full-year profit guidance to between $7.30 and $7.50 per share, up from its previous forecast of $7.00 to $7.20. The company also expects revenue for the year to reach at least $405 billion, an increase from the prior estimate of $400 billion. CVS’s Chief Financial Officer, Brian Newman, attributed the positive results to the strength of its insurance unit, Aetna, which recorded a revenue of $35.97 billion in Q1, a 3% increase from the same period last year and above analyst expectations.
Newman stated, "From an investor lens, we said let's put out realistic, reasonable targets and then find pathways to outperform. And we did that throughout at the end of last year and the quarter." He expressed cautious optimism about the company's performance, noting that medical costs remain high but that CVS is improving its ability to manage these costs.
The company’s net income for Q1 2026 was $2.94 billion, or $2.30 per share, compared to $1.78 billion, or $1.41 per share, in the same quarter of the previous year. This year-over-year growth reflects CVS's broader turnaround strategy, which has included cutting $2 billion in costs and closing underperforming stores. All business segments, including insurance, retail pharmacy, and health services, surpassed Wall Street’s revenue expectations, contributing to the company’s positive outlook.
CVS Health's turnaround efforts come after a challenging period marked by high medical costs and a competitive healthcare market. The company has faced scrutiny as major insurers, including Aetna, grappled with rising medical expenses due to an influx of patients returning to hospitals for delayed procedures during the pandemic. In response, CVS has implemented organizational changes aimed at improving operational efficiency.
One key metric for assessing the company's insurance performance is the medical benefit ratio (MBR), which indicates the percentage of premiums spent on medical services. CVS reported an MBR of 84.6% for its Aetna unit, a marked improvement from 87.3% in the previous year and below analysts' expectations of 87.58%. A lower ratio typically signals higher profitability, indicating that CVS collected more in premiums than it paid out in benefits.
Analysts have noted that this fifth consecutive quarterly earnings beat reflects CVS’s capacity to improve its financial health and operational effectiveness. The company’s health services segment, which includes its pharmacy benefit manager Caremark, reported a revenue increase of 11% for the quarter, driven by a more profitable mix of drugs and improved medical cost controls.
As CVS Health moves forward, the company is focused on maintaining its momentum and addressing the challenges posed by high medical costs. Newman emphasized the need for CVS to utilize its internal programs to reduce these costs effectively. The company is also working on enhancing its forecasting capabilities to avoid surprises related to medical expenses.
Looking ahead, CVS plans to continue its strategic initiatives, including the launch of Health100, a health technology services subsidiary that will leverage Google Cloud's AI technologies to provide a fully integrated healthcare engagement platform. This move aims to improve access to care and streamline operations across its various business segments.
The company's stock saw a substantial increase, rising nearly 6% in premarket trading following the earnings report. Institutional investor activity has been mixed in recent quarters, with 847 investors adding shares and 936 reducing their positions. Notable changes included UBS Asset Management removing over 23 million shares, whereas Wellington Management added more than 12 million shares to its portfolio.
CVS Health is also mindful of macroeconomic factors that could impact its operations, including potential regulatory changes and fluctuating healthcare costs. As the company prepares for the second quarter, it remains cautious yet optimistic about its ability to navigate these challenges effectively.
In a statement, CVS Health’s Chairman and CEO, David Joyner, remarked, "CVS Health continues to provide what people want most from healthcare: a connected, convenient, cost-effective engagement experience across our unique collection of businesses." This commitment to improving healthcare delivery is central to CVS's strategy as it seeks to build trust and provide quality care to nearly 185 million people across the country. The company will hold a conference call for investors today at 8:00 a.m. (Eastern Time) to discuss its first-quarter results in detail.
As CVS Health continues to build on its recent successes, the healthcare giant remains vigilant in its efforts to adapt to the ever-changing healthcare environment, aiming to simplify healthcare for individuals and families across America.